Evidence map›Paper›PMID 36208844›Full record

ArticleJournal of hepatology2022

Global burden of primary liver cancer in 2020 and predictions to 2040.

Harriet Rumgay, Melina Arnold, Jacques Ferlay, Olufunmilayo Lesi, Citadel J Cabasag, Jérôme Vignat, Mathieu Laversanne, Katherine A McGlynn, Isabelle Soerjomataram

2 registry-linked trialsAbstract read
In one paragraph

Article in Journal of hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1,291 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,291citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06535737 phase2not yet recruitingnot on this mapstarted 2024, after this paper: background citation

A Phase 2, Single Arm Study of Cabozantinib in Patients With Hepatocellular Carcinoma Who Have Received Prior Atezolizumab and Bevacizumab

TypeinterventionalSponsorChulalongkorn UniversityRan2024 to 2026Enrolled40ConditionsHepatocellular Carcinoma Non-resectableArmsCabozantinib
NCT07119957 narecruitingnot on this mapstarted 2025, after this paper: background citation

ProspEXPO : PROSPective Study of the Associations Between Hepatocellular Carcinoma and Chemical and Psychosocial Environmental EXPOsome

TypeinterventionalSponsorUniversity Hospital, AngersRan2025 to 2029Enrolled300ConditionsCirrhoses, Liver, Carcinoma LiverArmsBlood, urine and stool biocollection
3 · Its place in the literature

Who cites it

1,291 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

1,231 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Harriet RumgayInternational Agency for Research on Cancer (IARC/WHO), Cancer Surveillance Branch, Lyon, France. Electronic address: RumgayH@iarc.who.int.
Melina ArnoldInternational Agency for Research on Cancer (IARC/WHO), Cancer Surveillance Branch, Lyon, France.
Jacques FerlayInternational Agency for Research on Cancer (IARC/WHO), Cancer Surveillance Branch, Lyon, France.
Olufunmilayo LesiDepartment of Global HIV, Hepatitis and STIs Programme, World Health Organization, Geneva, Switzerland.
Citadel J CabasagInternational Agency for Research on Cancer (IARC/WHO), Cancer Surveillance Branch, Lyon, France.
Jérôme VignatInternational Agency for Research on Cancer (IARC/WHO), Cancer Surveillance Branch, Lyon, France.
Mathieu LaversanneInternational Agency for Research on Cancer (IARC/WHO), Cancer Surveillance Branch, Lyon, France.
Katherine A McGlynnDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, United States.
Isabelle SoerjomataramInternational Agency for Research on Cancer (IARC/WHO), Cancer Surveillance Branch, Lyon, France.

Funding

World Health Organization 001
6 · The paper itself

Abstract

BACKGROUND &

aimsThe burden of liver cancer varies across the world. Herein, we present updated estimates of the current global burden of liver cancer (incidence and mortality) and provide predictions of the number of cases/deaths to 2040.

methodsWe extracted data on primary liver cancer cases and deaths from the GLOBOCAN 2020 database, which includes 185 countries. Age-standardised incidence and mortality rates (ASRs) per 100,000 person-years were calculated. Cases and deaths up to the year 2040 were predicted based on incidence and mortality rates for 2020 and global demographic projections to 2040.

resultsIn 2020, an estimated 905,700 people were diagnosed with, and 830,200 people died from, liver cancer globally. Global ASRs for liver cancer were 9.5 and 8.7 for new cases and deaths, respectively, per 100,000 people and were highest in Eastern Asia (17.8 new cases, 16.1 deaths), Northern Africa (15.2 new cases, 14.5 deaths), and South-Eastern Asia (13.7 new cases, 13.2 deaths). Liver cancer was among the top three causes of cancer death in 46 countries and was among the top five causes of cancer death in 90 countries. ASRs of both incidence and mortality were higher among males than females in all world regions (male:female ASR ratio ranged between 1.2-3.6). The number of new cases of liver cancer per year is predicted to increase by 55.0% between 2020 and 2040, with a possible 1.4 million people diagnosed in 2040. A predicted 1.3 million people could die from liver cancer in 2040 (56.4% more than in 2020).

conclusionsLiver cancer is a major cause of death in many countries, and the number of people diagnosed with liver cancer is predicted to rise. Efforts to reduce the incidence of preventable liver cancer should be prioritised. LAY SUMMARY: The burden of liver cancer varies across the world. Liver cancer was among the top three causes of cancer death in 46 countries and was among the top five causes of cancer death in 90 countries worldwide. We predict the number of cases and deaths will rise over the next 20 years as the world population grows. Primary liver cancer due to some causes is preventable if control efforts are prioritised and the predicted rise in cases may increase the need for resources to manage care of patients with liver cancer.

Indexed as

Global HealthLiver NeoplasmsCause of DeathDatabases, FactualFemaleHumansIncidenceMalecancer registriesepidemiologyHepatocellular carcinomaintrahepatic cholangiocarcinoma

Identifiers

PMID36208844
PMCPMC9670241

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.